- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01733823
DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole
July 26, 2017 updated by: Danish Head and Neck Cancer Group
Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole for Patients With Stage III-IV p16 Negative Squamous Cell Cancer (SCC) of the Larynx, Pharynx and Oral Cavity
P16 negative cancers continue to have a dismal prognosis despite advances in the treatment of head and neck cancer.
Acceleration, dose-escalation, hyperfractionation, chemotherapy and nimorazole has been shown to improve local control.
The purpose of the study i to investigate the level of co-morbidity and performance status (PS) that allows the combination of all of the above means of treatment intensification
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
31
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Aalborg, Denmark, 9100
- Aalborg
-
Herlev, Denmark, 2730
- Herlev
-
-
Aarhus C
-
Aarhus, Aarhus C, Denmark, 8000
- Aarhus
-
-
Odense C
-
Odense, Odense C, Denmark, 5000
- Odense
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Squamous Cell Carcinoma head and neck cancer of the pharynx, larynx and oral cavity
- P16 negative
- T1-4
- N1-3
- M0
- Organ function and performance status allowing radical chemo-radiotherapy
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
Performance scale 0-1, Charlson co-morbidity score=0 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
|
|
Experimental: Group B
PS 0-1 Charlson=1 Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
|
|
Experimental: Group C
PS 0-1 Charlson >=2 Will start inclusion after Group A and B Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
|
|
Experimental: Group D
PS 2, Charlson: Any Will start inclusion after Group C Treatment: 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Compliance
Time Frame: End of radiotherapy (approximately 5.5 weeks after start of radiotherapy)
|
Proportion of patients that receive radiotherapy in accordance to prescribed dose and treatment time
|
End of radiotherapy (approximately 5.5 weeks after start of radiotherapy)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute toxicity
Time Frame: 2 months after end of radiotherapy
|
In accordance with the Danish Head and Neck Cancer Group (DAHANCA) toxicity scales
|
2 months after end of radiotherapy
|
Response rate
Time Frame: 2 months after end of radiotherapy
|
Proportion of complete and partial responders
|
2 months after end of radiotherapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jens Overgaard, MD, DMSc, Danish Head and Neck Cancer Group
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2013
Primary Completion (Actual)
March 1, 2016
Study Completion (Actual)
March 1, 2016
Study Registration Dates
First Submitted
November 8, 2012
First Submitted That Met QC Criteria
November 26, 2012
First Posted (Estimate)
November 27, 2012
Study Record Updates
Last Update Posted (Actual)
July 28, 2017
Last Update Submitted That Met QC Criteria
July 26, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DAHANCA 28A
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HNSCC,Larynx, Pharynx and Oral Cavity
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedLarynx | Lip, Oral Cavity and PharynxUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedLarynx | Oral Cavity | Lip | PharynxUnited States
-
Yonsei UniversityActive, not recruitingLarynx | Stage II-IVB Operable HNSCC Oral Cavity | Hypopharynx | OropharynxKorea, Republic of
-
Ohio State University Comprehensive Cancer CenterRecruitingTongue Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Verrucous Carcinoma of the Larynx | Recurrent Verrucous Carcinoma of the Oral Cavity | Recurrent Adenoid... and other conditionsUnited States
-
Wake Forest University Health SciencesTerminatedStage I Adenoid Cystic Carcinoma of the Oral Cavity | Stage I Mucoepidermoid Carcinoma of the Oral Cavity | Stage I Squamous Cell Carcinoma of the Hypopharynx | Stage I Squamous Cell Carcinoma of the Larynx | Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage I Verrucous Carcinoma... and other conditionsUnited States
-
Maria Sklodowska-Curie National Research Institute...Medical Research Agency, PolandRecruitingParanasal Sinus Carcinoma | Squamous Cell Carcinoma of Oral Cavity | Larynx Carcinoma | Pharynx CarcinomaPoland
-
Ohio State University Comprehensive Cancer CenterCompletedTongue Cancer | Salivary Gland Squamous Cell Carcinoma | Stage I Salivary Gland Cancer | Stage I Squamous Cell Carcinoma of the Hypopharynx | Stage I Squamous Cell Carcinoma of the Larynx | Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage I Squamous Cell Carcinoma of the Nasopharynx and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMucositis | Tongue Cancer | Oral Complications | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Verrucous Carcinoma of the Larynx | Recurrent... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)TerminatedRecurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous Cell Carcinoma of the Oropharynx | Recurrent Verrucous Carcinoma of the Larynx | Recurrent Verrucous Carcinoma... and other conditionsUnited States
-
Thomas Jefferson UniversityBristol-Myers SquibbActive, not recruitingLarynx | Squamous Cell Carcinoma | Lip | Oral Cavity Squamous Cell Carcinoma | PharynxUnited States